<DOC>
	<DOCNO>NCT00151684</DOCNO>
	<brief_summary>The purpose study explore diazoxide efficacy treatment obese men assessment maximal insulin suppression obese men without hyperglycaemia . Obesity associate markedly elevate plasma insulin level throughout day . The concept obese subject predominantly develop lean tissue resistance glucoregulatory action insulin , remain relatively sensitive lipogenic antilipolytic effect insulin adipose tissue . According theory , suppression hyperinsulinism diazoxide , well know inhibitor glucose stimulate insulin secretion , might useful treat obesity help reverse process lipid storage .</brief_summary>
	<brief_title>Diazoxide-Mediated Insulin Suppression Hyperinsulinemic Obese Men</brief_title>
	<detailed_description>The purpose study explore diazoxide efficacy treatment obese men assessment maximal insulin suppression obese men without hyperglycaemia . Study design : This study open-labelled , non-randomized , phase IIa study . Treatment : During 6 month period , dosage Diazoxide raise gradually maximum 900 mg/day , control bloodpressure glucose level . Endpoints , monthly determine : - body weight - abdominal circumference - body composition measure Dual Energy X-ray Absorptiometry - glucose tolerance</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>fast glucose &lt; 7.0 mmol/L fast Cpeptide plasma level &gt; 1.0 nmol/L HbA1c 6.0 % low Absence comorbidity Absence medication use Plasma Creatinine &gt; 120 micromol/L Liverenzymes &gt; 2 time upper normal limit Gout Alcohol use &gt; 2 units/day Illicit drug use Quit smoking le 6 month ago</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Hyperinsulinism</keyword>
	<keyword>Diazoxide</keyword>
</DOC>